Loading market dashboard
Basel Medical Group Ltd Ordinary Shares
BMGLHealthcareNASDAQSG
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
LOS ANGELES, April 23, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Basel Medical Group Ltd (“Basel” or “the Company”) (NASDAQ: BMGL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Basel Medical Group Ltd. (NASDAQ: BMGL) resulting from allegations that Basel Medical may have issued materially misleading business information to the investing public. So what: If you purchased Basel Medical securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency.
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Basel Medical Group Ltd. (NASDAQ: BMGL) resulting from allegations that Basel Medical may have issued materially misleading business information to the investing public. So what: If you purchased Basel Medical securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency.
Singapore, March 24, 2026 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL) (the “Company”) today announced that it has received notification from Nasdaq that based on the Company's amended annual report on Form 20-F for the fiscal year of 2025, which was filed with the SEC on March 13, 2026, Nasdaq Staff has now determined that the Company has complied with the periodic filing requirement for The Nasdaq Stock Market under Listing Rule 5250(c)(1) (the “Periodic Filing Rule”). Accordingly, the prior deficiency relating to the Periodic Filing Rule has now been resolved.
